| Product Code: ETC12910447 | Publication Date: Apr 2025 | Updated Date: Sep 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sachin Kumar Rai | No. of Pages: 65 | No. of Figures: 34 | No. of Tables: 19 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Israel Mannose Phosphate Isomerase Deficiency Market Overview |
3.1 Israel Country Macro Economic Indicators |
3.2 Israel Mannose Phosphate Isomerase Deficiency Market Revenues & Volume, 2021 & 2031F |
3.3 Israel Mannose Phosphate Isomerase Deficiency Market - Industry Life Cycle |
3.4 Israel Mannose Phosphate Isomerase Deficiency Market - Porter's Five Forces |
3.5 Israel Mannose Phosphate Isomerase Deficiency Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.6 Israel Mannose Phosphate Isomerase Deficiency Market Revenues & Volume Share, By Treatment Type, 2021 & 2031F |
3.7 Israel Mannose Phosphate Isomerase Deficiency Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.8 Israel Mannose Phosphate Isomerase Deficiency Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 Israel Mannose Phosphate Isomerase Deficiency Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing awareness about rare genetic disorders like Israel Mannose Phosphate Isomerase Deficiency (MPI-CDG) among healthcare professionals and patients. |
4.2.2 Advances in genetic testing technologies leading to early and accurate diagnosis of MPI-CDG. |
4.2.3 Growing research and development activities aimed at developing novel treatments and therapies for MPI-CDG patients. |
4.3 Market Restraints |
4.3.1 Limited availability and high cost of specialized treatments for MPI-CDG. |
4.3.2 Challenges in obtaining regulatory approvals for new therapies due to the rarity of the condition and limited patient population. |
4.3.3 Lack of standardized treatment guidelines for managing MPI-CDG, leading to variability in patient care. |
5 Israel Mannose Phosphate Isomerase Deficiency Market Trends |
6 Israel Mannose Phosphate Isomerase Deficiency Market, By Types |
6.1 Israel Mannose Phosphate Isomerase Deficiency Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 Israel Mannose Phosphate Isomerase Deficiency Market Revenues & Volume, By Type, 2021 - 2031F |
6.1.3 Israel Mannose Phosphate Isomerase Deficiency Market Revenues & Volume, By Genetic Disorder, 2021 - 2031F |
6.1.4 Israel Mannose Phosphate Isomerase Deficiency Market Revenues & Volume, By Metabolic Disease, 2021 - 2031F |
6.1.5 Israel Mannose Phosphate Isomerase Deficiency Market Revenues & Volume, By Rare Disease, 2021 - 2031F |
6.2 Israel Mannose Phosphate Isomerase Deficiency Market, By Treatment Type |
6.2.1 Overview and Analysis |
6.2.2 Israel Mannose Phosphate Isomerase Deficiency Market Revenues & Volume, By Enzyme Replacement Therapy, 2021 - 2031F |
6.2.3 Israel Mannose Phosphate Isomerase Deficiency Market Revenues & Volume, By Supportive Therapy, 2021 - 2031F |
6.2.4 Israel Mannose Phosphate Isomerase Deficiency Market Revenues & Volume, By Gene Therapy, 2021 - 2031F |
6.3 Israel Mannose Phosphate Isomerase Deficiency Market, By Route of Administration |
6.3.1 Overview and Analysis |
6.3.2 Israel Mannose Phosphate Isomerase Deficiency Market Revenues & Volume, By Oral, 2021 - 2031F |
6.3.3 Israel Mannose Phosphate Isomerase Deficiency Market Revenues & Volume, By Intravenous, 2021 - 2031F |
6.3.4 Israel Mannose Phosphate Isomerase Deficiency Market Revenues & Volume, By Injection, 2021 - 2031F |
6.4 Israel Mannose Phosphate Isomerase Deficiency Market, By End User |
6.4.1 Overview and Analysis |
6.4.2 Israel Mannose Phosphate Isomerase Deficiency Market Revenues & Volume, By Hospitals & Clinics, 2021 - 2031F |
6.4.3 Israel Mannose Phosphate Isomerase Deficiency Market Revenues & Volume, By Research & Diagnostic Centers, 2021 - 2031F |
6.4.4 Israel Mannose Phosphate Isomerase Deficiency Market Revenues & Volume, By Pharmaceutical & Biotechnology, 2021 - 2031F |
7 Israel Mannose Phosphate Isomerase Deficiency Market Import-Export Trade Statistics |
7.1 Israel Mannose Phosphate Isomerase Deficiency Market Export to Major Countries |
7.2 Israel Mannose Phosphate Isomerase Deficiency Market Imports from Major Countries |
8 Israel Mannose Phosphate Isomerase Deficiency Market Key Performance Indicators |
8.1 Average age of diagnosis of MPI-CDG patients, indicating improvements in early detection and diagnosis. |
8.2 Number of clinical trials and research studies focused on developing treatments for MPI-CDG. |
8.3 Patient-reported outcomes measures related to quality of life improvements in MPI-CDG patients undergoing treatment. |
9 Israel Mannose Phosphate Isomerase Deficiency Market - Opportunity Assessment |
9.1 Israel Mannose Phosphate Isomerase Deficiency Market Opportunity Assessment, By Type, 2021 & 2031F |
9.2 Israel Mannose Phosphate Isomerase Deficiency Market Opportunity Assessment, By Treatment Type, 2021 & 2031F |
9.3 Israel Mannose Phosphate Isomerase Deficiency Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.4 Israel Mannose Phosphate Isomerase Deficiency Market Opportunity Assessment, By End User, 2021 & 2031F |
10 Israel Mannose Phosphate Isomerase Deficiency Market - Competitive Landscape |
10.1 Israel Mannose Phosphate Isomerase Deficiency Market Revenue Share, By Companies, 2024 |
10.2 Israel Mannose Phosphate Isomerase Deficiency Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here